Efficacy in selected tumor types in a phase I study of the c-MET inhibitor ARQ 197 in combination with sorafenib.
JOURNAL OF CLINICAL ONCOLOGY (2011)
期刊
JOURNAL OF CLINICAL ONCOLOGY
卷 29, 期 15, 页码 -出版社
AMER SOC CLINICAL ONCOLOGY
关键词
类别
作者
我是这篇论文的作者
推荐
Resistance to MET inhibition in MET-dependent NSCLC and therapeutic activity after switching from type I to type II MET inhibitors
Richard Riedel, Jana Fassunke, Hannah L. Tumbrink, Andreas H. Scheel, Carina Heydt, Lena Hieggelke, Matthias Scheffler, Alena Heimsoeth, Lucia Nogova, Sebastian Michels, Jan-Phillip Weber, Rieke N. Fischer, Anna Eisert, Theresa Westphal, Diana Schaufler, Janna Siemanowski, Michaela A. Ihle, Svenja Wagener-Ryczek, Roberta Castiglione, Roberto Pappesch, Jan Rehker, Jessica Juergens, Erich Stoelben, Anne Bunck, Carsten Kobe, Sabine Merkelbach-Bruse, Martin L. Sos, Reinhard Buettner, Juergen Wolf
EUROPEAN JOURNAL OF CANCER (2023)
Recent advances of sorafenib nanoformulations for cancer therapy: Smart nanosystem and combination therapy
Fangmin Chen, Yifan Fang, Xiang Chen, Rui Deng, Yongjie Zhang, Jingwei Shao
ASIAN JOURNAL OF PHARMACEUTICAL SCIENCES (2021)
Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression
Baek-Yeol Ryoo, Ann-Li Cheng, Zhenggang Ren, Tae-You Kim, Hongming Pan, Kun-Ming Rau, Hye Jin Choi, Joong-Won Park, Jee Hyun Kim, Chia Jui Yen, Ho Yeong Lim, Dongli Zhou, Josef Straub, Juergen Scheele, Karin Berghoff, Shukui Qin
BRITISH JOURNAL OF CANCER (2021)
Targeting c-MET to Enhance the Efficacy of Olaparib in Prostate Cancer
Zhenwei Wang, Zhihong Dai, Bingwei Wang, Yuren Gao, Xiang Gao, Liang Wang, Sihai Zhou, Liqin Yang, Xiaofu Qiu, Zhiyu Liu
ONCOTARGETS AND THERAPY (2021)
Antileukemic efficacy of a potent artemisinin combined with sorafenib and venetoclax
Blake S. Moses, Samantha McCullough, Jennifer M. Fox, Bryan T. Mott, Soren M. Bentzen, MinJung Kim, Jeffrey W. Tyner, Rena G. Lapidus, Ashkan Emadi, Michelle A. Rudek, Tami J. Kingsbury, Curt Civin
BLOOD ADVANCES (2021)
A randomized, double-blind, placebo- controlled phase II study to evaluate the efficacy and safety of ivarmacitinib (SHR0302) in adult patients with moderate-to-severe alopecia areata
Cheng Zhou, Xiumin Yang, Bin Yang, Guofu Yan, Xiuqin Dong, Yangfeng Ding, Weixin Fan, Linfeng Li, Dingquan Yang, Hong Fang, Chao Ji, Hao Cheng, Shoumin Zhang, Aik Han Goh, Rongjun Liu, Xiaoyu Gu, Zaili Weng, Peter Foley, Rodney Sinclair, Jianzhong Zhang
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2023)
Case Report: Sequential Combination Targeted Therapy With Type I and II MET Inhibitors in a Metastatic EGFR-Mutated, MET-Amplified NSCLC Patient With Acquired MET Y1230H Mutation
Boning Cai, Xiaomo Li, Xiang Huang, Tonghui Ma, Baolin Qu, Wei Yu, Wei Yang, Pei Zhang, Jing Chen, Fang Liu
FRONTIERS IN ONCOLOGY (2021)
Enhanced oral bioavailability and antitumor therapeutic efficacy of sorafenib administered in core-shell protein nanoparticle
Lekshmi Gopakumar, Maya Sreeranganathan, Shalin Chappan, Sneha James, Genekehal Siddaramana Gowd, Maneesh Manohar, Arya Sukumaran, Ayalur Kodakara Kochugovindan Unni, Shantikumar Vasudevan Nair, Manzoor Koyakutty
DRUG DELIVERY AND TRANSLATIONAL RESEARCH (2022)
Phase I Targeted Combination Trial of Sorafenib and GW5074 in Patients with Advanced Refractory Solid Tumors
Chien-Chang Kao, Ching-Liang Ho, Ming-Hsin Yang, Yi-Ta Tsai, Shu-Yu Liu, Ping-Ying Chang, Yi-Ying Wu, Jia-Hong Chen, Ren-Hua Yehn, Ming-Shen Dai, Yeu-Chin Chen, Guang-Huan Sun, Tai-Lung Cha
JOURNAL OF CLINICAL MEDICINE (2022)
Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma
Ann-Lii Cheng, Shukui Qin, Masafumi Ikeda, Peter R. Galle, Michel Ducreux, Tae-You Kim, Ho Yeong Lim, Masatoshi Kudo, Valeriy Breder, Philippe Merle, Ahmed O. Kaseb, Daneng Li, Wendy Verret, Ning Ma, Alan Nicholas, Yifan Wang, Lindong Li, Andrew X. Zhu, Richard S. Finn
JOURNAL OF HEPATOLOGY (2022)
A Phase I Study of a Combination of Liposomal Irinotecan and Veliparib in Solid Tumors
Meredith LaRose, Roisin M. Connolly, Ciara C. O'Sullivan, Vamsidhar Velcheti, Rasa Vilimas, Katherine Gano, Susan E. Bates, Yves Pommier, Anish Thomas
ONCOLOGIST (2023)
Histone deacetylase inhibitor resminostat in combination with sorafenib counteracts platelet-mediated pro-tumoral effects in hepatocellular carcinoma
Gundula Streubel, Sabine Schrepfer, Hannah Kallus, Ulrike Parnitzke, Tanja Wulff, Frank Hermann, Matthias Borgmann, Svetlana Hamm
SCIENTIFIC REPORTS (2021)
The combination of PRL-3 inhibitor with sorafenib synergistically promotes AML apoptosis
Xiaomin Chen, Dade Rong, Wanhua Cai, Xiuzhen Tong, Haihe Wang
NEOPLASMA (2021)
A Combination of Sorafenib, an Immune Checkpoint Inhibitor, TACE and Stereotactic Body Radiation Therapy versus Sorafenib and TACE in Advanced Hepatocellular Carcinoma Accompanied by Portal Vein Tumor Thrombus
Zeyu Zhang, Chan Li, Weijun Liao, Yun Huang, Zhiming Wang
CANCERS (2022)
Preclinical characterization and phase I clinical trial of CT053PTSA targets MET, AXL, and VEGFR2 in patients with advanced solid tumors
Yu-Xiang Ma, Fu-Rong Liu, Yang Zhang, Qun Chen, Zhi-Qiang Chen, Qian-Wen Liu, Yan Huang, Yun-Peng Yang, Wen-Feng Fang, Ning Xi, Ning Kang, Yu-Lei Zhuang, Qi Zhang, Ying-Zhi Jiang, Li Zhang, Hong-Yun Zhao
FRONTIERS IN IMMUNOLOGY (2022)
Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF-Mutant Melanoma
Antoni Ribas, Adil Daud, Anna C. Pavlick, Rene Gonzalez, Karl D. Lewis, Omid Hamid, Thomas F. Gajewski, Igor Puzanov, Matthew Wongchenko, Isabelle Rooney, Jessie J. Hsu, Yibing Yan, Erica Park, Grant A. McArthur
CLINICAL CANCER RESEARCH (2020)
Intratumoral Immunotherapy-Update 2019
Omid Hamid, Rubina Ismail, Igor Puzanov
ONCOLOGIST (2020)
Pembrolizumab for the treatment of programmed death-ligand 1-positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study
Janice M. Mehnert, Emily Bergsland, Bert H. O'Neil, Armando Santoro, Jan H. M. Schellens, Roger B. Cohen, Toshihiko Doi, Patrick A. Ott, Michael J. Pishvaian, Igor Puzanov, Kyaw L. Aung, Chiun Hsu, Christophe Le Tourneau, Antoine Hollebecque, Elena Elez, Kenji Tamura, Marlena Gould, Ping Yang, Karen Stein, Sarina A. Piha-Paul
CANCER (2020)
Anti-IL6R role in treatment of COVID-19-related ARDS
Franco Maria Buonaguro, Igor Puzanov, Paolo Antonio Ascierto
JOURNAL OF TRANSLATIONAL MEDICINE (2020)
The Great Debate at Melanoma Bridge, Naples, December 7th, 2019
Paolo A. Ascierto, Sanjiv S. Agarwala, Alexander Eggermont, Jeffrey E. Gershenwald, Jean-Jacques Grob, Omid Hamid, Olivier Michielin, Michael Postow, Igor Puzanov, Hassane M. Zarour, Corrado Caraco, Alessandro Testori
JOURNAL OF TRANSLATIONAL MEDICINE (2020)
COVID-19 and Cancer: a Comprehensive Review
Rohit Gosain, Yara Abdou, Abhay Singh, Navpreet Rana, Igor Puzanov, Marc S. Ernstoff
CURRENT ONCOLOGY REPORTS (2020)
T-cell CX3CR1 expression as a dynamic blood-based biomarker of response to immune checkpoint inhibitors
Takayoshi Yamauchi, Toshifumi Hoki, Takaaki Oba, Vaibhav Jain, Hongbin Chen, Kristopher Attwood, Sebastiano Battaglia, Saby George, Gurkamal Chatta, Igor Puzanov, Carl Morrison, Kunle Odunsi, Brahm H. Segal, Grace K. Dy, Marc S. Ernstoff, Fumito Ito
NATURE COMMUNICATIONS (2021)
Managing Metastatic Melanoma in 2022: A Clinical Review
Benjamin Switzer, Igor Puzanov, Joseph J. Skitzki, Lamya Hamad, Marc S. Ernstoff
JCO ONCOLOGY PRACTICE (2022)
Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma
Jason A. Chesney, Antoni Ribas, Georgina Long, John M. Kirkwood, Reinhard Dummer, Igor Puzanov, Christoph Hoeller, Thomas F. Gajewski, Ralf Gutzmer, Piotr Rutkowski, Lev Demidov, Petr Arenberger, Sang Joon Shin, Pier Francesco Ferrucci, Andrew Haydon, John Hyngstrom, Johannes van Thienen, Sebastian Haferkamp, Josep Malvehy Guilera, Bernardo Leon Rapoport, Ari VanderWalde, Scott J. Diede, James R. Anderson, Sheryl Treichel, Edward L. Chan, Sumita Bhatta, Jennifer Gansert, Frank Stephen Hodi, Helen Gogas
JOURNAL OF CLINICAL ONCOLOGY (2023)
Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open- label, phase II trial
Jason A. Chesney, Igor Puzanov, Frances A. Collichio, Parminder Singh, Mohammed M. Milhem, John Glaspy, Omid Hamid, Merrick Ross, Philip Friedlander, Claus Garbe, Theodore Logan, Axel Hauschild, Celeste Lebbe, Harshada Joshi, Wendy Snyder, Janice M. Mehnert
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2023)
The T Cell Immunoscore as a Reference for Biomarker Development Utilizing Real-World Data from Patients with Advanced Malignancies Treated with Immune Checkpoint Inhibitors
Islam Eljilany, Payman Ghasemi Saghand, James Chen, Aakrosh Ratan, Martin McCarter, John Carpten, Howard Colman, Alexandra P. Ikeguchi, Igor Puzanov, Susanne Arnold, Michelle Churchman, Patrick Hwu, Jose Conejo-Garcia, William S. Dalton, George J. Weiner, Issam M. El Naqa, Ahmad A. Tarhini
CANCERS (2023)
Risk of Further Progression or Death Among Durable Progression-Free Survivors With Melanoma or Non-Small-Cell Lung Cancer in PD-1 Blockade Trials: Implications for Imaging Surveillance
Lei Deng, Changchuan Jiang, Kristopher Attwood, Joseph J. Zhao, Stuthi Perimbeti, Chen Hu, Igor Puzanov, Grace K. Dy
JCO ONCOLOGY PRACTICE (2023)
Identifying strategies to address obstacles to optimal integration of cancer immunotherapies in the community
Latha Shivakumar, Christine B. Weldon, Ali McBride, Igor Puzanov, Joanne Riemer, Matthew R. Zibelman, Leigh Boehmer
JOURNAL OF CLINICAL ONCOLOGY (2020)
Clinical activity of BEMPEG plus NIVO in previously untreated patients with metastatic melanoma: updated results from the phase 1/2 PIVOT-02 study
Adi Diab, Igor Puzanov, Michele Maio, Brendan Curti, Mehmet Bilen, Karl Lewis, Scott Tykodi, Gregory Daniels, Alexander Spira, Chantale Bernatchez, Salah Eddine Bentebibel, Michael Wong, James Larkin, Ewa Kalinka-Warzocha, Sunny Xie, Sue Currie, Ute Hoch, Wei Lin, Mary Tagliaferri, Stina Singel, Michael Hurwitz
JOURNAL OF TRANSLATIONAL MEDICINE (2020)
Activation of innate and adaptive immunity using intratumoral tilsotolimod (IMO-2125) as monotherapy in patients with refractory solid tumors: a phase 1b study (ILLUMINATE-101)
Hani M. Babiker, Vivek Subbiah, Orla Maguire, Shah Rahimian, Hans Minderman, Cara L. Haymaker, Chantale Bernatchez, Erkut Borazanci, James Geib, Srinivas K. Chunduru, Peter M. Anderson, Igor Puzanov, Adi Diab
CANCER RESEARCH (2019)